Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China : vimarsana.com

Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

/PRNewswire/ -- Jacobio Pharma (1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor...

Related Keywords

China , Beijing , Boston , Massachusetts , United States , Shanghai , Jacobio Pharma , Investigational New Drug , Drug Evaluation ,

© 2024 Vimarsana